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Background: Nickel nanoparticles (NiNPs) are increasingly used in a variety of industrial applications, including the
manufacturing of multi-walled carbon nanotubes (MWCNTs). While occupational nickel exposure is a known cause
of pulmonary alveolitis, fibrosis, and cancer, the health risks of NiNPs are not well understood, especially in susceptible
individuals such as asthmatics. The T-box transcription factor Tbx21 (T-bet) maintains Th1 cell development and loss of
T-bet is associated with a shift towards Th2 type allergic airway inflammation that characterizes asthma. The purpose of
this study was to determine the role of T-bet in susceptibility to lung remodeling by NiNPs or MWCNTs.
Methods: Wild-type (WT) and T-bet−/− mice were exposed to NiNPs or MWCNTs (4 mg/kg) by oropharyngeal
aspiration (OPA). Necropsy was performed at 1 and 21 days. Bronchoalveolar lavage fluid (BALF) was collected
for differential counting of inflammatory cells and for measurement of cytokines by ELISA. The left lung was collected
for histopathology. The right lung was analyzed for cytokine or mucin (MUC5AC and MUC5B) mRNAs.
Results: Morphometry of alcian-blue/periodic acid Schiff (AB/PAS)-stained lung tissue showed that NiNPs significantly
increased mucous cell metaplasia in T-bet−/− mice at 21 days (p < 0.001) compared to WT mice, and increased MUC5AC
and MUC5B mRNAs (p < 0.05). MWCNTs also increased mucous cell metaplasia in T-bet−/− mice, but to a lesser extent
than NiNPs. Chronic alveolitis was also increased by NiNPs, but not MWCNTs, in T-bet−/− mice compared to WT mice at
21 days (P < 0.001). NiNPs also increased IL-13 and eosinophils (p < 0.001) in BALF from T-bet−/− mice after 1 day.
Interestingly, the chemokine CCL2 in the BALF of T-bet−/− mice was increased at 1 and 21 days (p < 0.001 and p < 0.05,
respectively) by NiNPs, and to a lesser extent by MWCNTs at 1 day. Treatment of T-bet−/− mice with a monoclonal
anti-CCL2 antibody enhanced NiNP-induced mucous cell metaplasia and MUC5AC mRNA levels (p < 0.05), yet
marginally reduced NiNP-induced alveolitis.
Conclusion: These findings identify T-bet as a potentially important susceptibility factor for NiNP exposure and
to a lesser extent for MWCNT exposure, and suggests that individuals with asthma are at greater risk.
Keywords: Nickel nanoparticles, Carbon nanotubes, T-bet, Asthma, Lung injuryBackground
Asthma is a chronic inflammatory disease of the air-
ways that currently affects more than 25 million people
in the United States and 300 million people worldwide
[1]. It is characterized by periods of acute bronchocon-
striction defined by airway hyperresponsiveness, mucus
hypersecretion, and airway remodeling that involves* Correspondence: james_bonner@ncsu.edu
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position, airway smooth muscle cell hypertrophy and
hyperplasia, and mucous cell metaplasia (a phenotypic
shift of the mucus-producing airway epithelium from
serous cells to mucus-laden goblet cells) [2]. Exposure
to allergens, viral infections, and environmental and
occupational irritants, such as particulate matter, often
trigger asthma exacerbations that lead to airflow ob-
struction through exaggerated inflammation and in-
creased mucus production [3]. Ultrafine particulate
matter <100 nm (i.e., nanoparticles) are of concern inntral Ltd. This is an Open Access article distributed under the terms of the
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tal areas of the lung and possess greater surface area
per unit mass as compared to larger particles [4].
Environmental, occupational, and genetic factors are
thought to act together to initiate allergen-mediated air-
way inflammation through T cell activation [5]. Early
studies found increased numbers of T helper 2 (Th2)
cells in the airways of asthmatics and defined them as
the key players in regulating allergic lung inflammation.
In turn, Th2 cells secrete elevated levels of the cytokines
IL-4, IL-5, and IL-13 through the transcription factor
GATA-3 that initiates and maintains the inflammatory
response [6,7]. The T-box transcription factor TBX21
(T-bet), maintains Th1 cell differentiation in the lung
and regulates the production of IFN-γ while inhibiting
the development of Th2 cells [8-10]. Mice with a tar-
geted deletion of T-bet (T-bet−/−) have decreased amounts
of IFN-γ and overproduce Th2 cytokines [8]. The lungs of
T-bet−/− mice have been reported to display spontaneous
airway remodeling, subepithelial collagen deposition, IL-13
mediated airway hyper-reactivity (AHR) and eosinophil
infiltration, similar to an asthma-like phenotype [9].
Interestingly, the airways of asthmatics have been shown
to have significantly less T-bet expression when compared
to non-asthmatic lungs suggesting that T-bet−/− mice
would be a useful Th2-mediated model of asthma [10].
The rapidly growing nanotechnology industry has led
to the manufacture of an increasing variety of novel
engineered nanomaterials (ENMs). Because of their unique
chemical and physical properties, ENMs could interact with
biological systems in ways that differ from that of bulk
materials composed of the same elemental composition, thus
preventing the ability to accurately predict how ENMs will
impact human health and the environment [4,11,12]. The
inhalation of nickel (Ni), particularly in occupational set-
tings, acutely causes inflammation and allergic reactions,
while chronic exposure to Ni has been linked to pulmon-
ary fibrosis, chronic alveolitis and lung cancer [13,14]. There-
fore, it is likely that nickel nanoparticles (NiNPs) could pose
similar threats to human health, yet information on human
disease caused by NiNPs is lacking. We and others have
shown that NiNPs are potent activators of mitogen-activated
protein kinases (MAPK) and hypoxia-inducible factor
(HIF)-1α in pleural mesothelial cells or lung epithelial
cells [15,16]. NiNP and Ni-based nanoparticles are also
more toxic than micron-sized Ni particles [16]. More-
over, NiNP compounds cause greater pulmonary in-
flammation and toxicity in the lungs of rodents when
directly compared to Ni particle counterparts [17-19].
NiNPs are widely used as catalysts for the manufacture
of multi-walled carbon nanotubes (MWCNTs). We have
shown that MWCNTs manufactured with a NiNP cata-
lyst exacerbate airway fibrosis in mice with pre-existing
allergic lung inflammation, suggesting that these ENMspose a potential health risk for susceptible individuals
with asthma [20]. More recently, we demonstrated that
susceptibility to MWCNT-induced airway inflammation
following allergen challenge was enhanced by the loss of
cyclooxygenase-2 (COX-2), indicating that the loss of
specific genes could be important determinants in sus-
ceptibility to ENMs [21]. In this study we analyzed the
effects of NiNPs on the exacerbation of allergic lung
inflammation in T-bet−/− mice, a genetically modified
mouse model of Th2-mediated allergic lung inflamma-
tion. We found that NiNPs increased mucous cell meta-
plasia in T-bet−/− mice 21 days after initial exposure but
not in wild-type (WT) mice. Additionally, mediators of
mucus regulation, IL-13 and CCL2, as well as eosinophil
infiltration, were increased in T-bet−/− mice in response
to NiNP. Interestingly, chronic alveolitis a hallmark re-
sponse of occupational nickel exposure, was enhanced in
T-bet−/− mice. Our findings suggest that individuals with
T-bet deficiency are more susceptible to allergic airway
remodeling or chronic alveolitis from NiNP exposure.
Results
Mucous cell metaplasia is amplified in T-bet deficient
mice after NiNP exposure
Wild-type (WT) and T-bet knockout (T-bet−/−) mice
were exposed to nickel nanoparticles (NiNPs) or multi-
walled carbon nanotubes (MWCNTs) by oropharyngeal
aspiration (OPA) and lung tissue was harvested 1 day or
21 days after initial exposure. The effect of NiNPs on
mucous cell metaplasia was evaluated first using semi-
quantitative scoring of AB/PAS-stained lung sections as
described in Materials & Methods (%PAS+/Total Area)
to identify the relative area of airway epithelium repre-
sented by mucin-producing goblet cells. Data from these
measurements showed that NiNP exposure increased
mucous cell metaplasia in WT or T-bet−/− mice at 1 day,
although this increase was not significant compared to
controls or between genotypes (Figure 1A). After 21 days,
NiNPs caused a robust and highly significant increase in
mucous cell metaplasia in T-bet−/− mice, while WT mice ex-
posed to NiNPs showed only a slight increase in mucous cell
metaplasia that was not statistically significant (Figure 1A).
Photomicrographs of AB/PAS-stained lung sections portray-
ing representative airways at 21 days post exposure showed
relatively few goblet cells in the airways of WT mice after
exposure to NiNPs, indicating relatively weak mucous cell
metaplasia (Figure 1B). However, in T-bet−/− mice, mucous
cell metaplasia dramatically increased after NiNP exposure
(Figure 1B). Higher magnification of the airways revealed al-
veolar macrophages containing NiNPs in close proximity to
goblet cells in both genotypes (Figure 1C). MWCNTs also
significantly increased mucous cell metaplasia in the lungs
of T-bet−/− mice, but to a significantly lesser extent as that






























































Figure 1 Mucous cell metaplasia in response to NiNP exposure in WT and T-bet−/− mice. A) Quantification of mucus producing cells at 1
or 21 days post-exposure determined using ImageJ analysis software (NIH). Data presented as the percentage of AB/PAS-positive stained area per
total area. ***p < 0.001 compared to the control group of the same genotype or as indicated. All data represent mean values ± SEM of at least
three measurements per lung of 5–7 mice per exposure group. B) Low magnification (10×) of AB/PAS stained lung tissue sections (open arrows)
at 21 days after WT and T-bet−/− mice were exposed to a 0.1% pluronic solution or NiNP. Asterisk indicates area of fibrosis. C) High magnification
(40× and 100×) of insert from 10× in (B). Black arrows indicate alveolar macrophages containing NiNP agglomerates.
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in T-bet−/− mice
Since mucous cell metaplasia was increased in T-bet−/−
mice in response to NiNPs, we measured MUC5AC and
MUC5B mRNA expression levels in whole lung tissue.
Levels of MUC5AC mRNA were increased in the lungs
of T-bet−/− mice one day after NiNP exposure, albeit not
to a significant extent. However, MUC5AC mRNA levels
were significantly increased in T-bet−/− mice at 21 days
after NiNP exposure compared to NiNP-treated WT
mice (Figure 2A). MUC5B mRNA in whole lung tissue
was also significantly increased at 1 day and 21 days post
NiNP exposure in T-bet−/− mice compared to NiNP-
treated WT mice (Figure 2B). NiNPs did not have a
significant effect on MUC5AC or MUC5B mRNA ex-
pression in WT mice at either time point. The Taqman
quantitative RT-PCR results shown in Figure 2 sup-
ported the semi-quantitative pathology scoring of mu-
cous cell metaplasia in T-bet−/− mice exposed to NiNPs
(Figure 1). MWCNTs also increased MUC5AC mRNA
levels 2 to 3-fold in the lungs of T-bet−/− mice, although
this increase was not statistically significant compared to
saline control and was significantly lower than the induc-






























































Figure 2 MUC5AC and MUC5B mRNA levels at 1 and 21 days after ex
changes in whole lung mRNA levels of A) MUC5AC and B) MUC5B. Values a
as compared to the control group of the same genotype or as indicated.T-bet−/− mice display spontaneous eosinophilia that is
enhanced by NiNPs
Numbers of eosinophils in BALF were spontaneously in-
creased at 1 and 21 days in the BALF of all T-bet−/−
mice compared to WT mice (Figure 3A). Furthermore,
NiNP exposure caused an exaggerated and transient in-
crease in eosinophils in T-bet−/− mice 1 day after treat-
ment. In comparison to NiNPs, MWCNTs did not
significantly increase numbers of eosinophils above 0.1%
pluronic control in T-bet−/− mice at 1 day (Additional file
2A). Lymphocyte counts were also slightly higher in the
BALF of T-bet−/− mice at 1 day and significantly increased
in response to NiNP exposure by 21 days (Figure 3B).
However, the overall number of lymphocytes remained
low in both WTand T-bet−/− mice in comparison to other
inflammatory cell types. NiNP exposure increased num-
bers of neutrophils in BALF after 1 day in either WT or
T-bet−/− mice (Figure 3C). MWCNTs also significantly in-
creased numbers of neutrophils in BALF in both WT and
T-bet−/−, although to a lesser extent compared to NiNP
exposure (Additional file 2B). Neutrophil number de-
creased by 21 days but still remained significantly elevated
in NiNP-treated WT and T-bet−/− mice (Figure 3C). Con-






























































posure. Taqman quantitative real-time RT-PCR was used to measure
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Figure 3 Differential cell counts in the BALF 1 and 21 day after NiNP exposure. Immune cells numbers for A) eosinophils, B) lymphocytes,
C) neutrophils, and D) macrophages are presented as the mean values ± SEM out of a total of 500 cells counted per animal for 5–7 animals per
dose group at 20× magnification. *p < 0.05, **p < 0.01, ***p < 0.001 compared to the time matched control group of the same genotype or as
indicated. E) Photomicrographs representing each cell type. Macrophages and neutrophils demonstrated phagocytosis of NiNP in both
genotypes at both time points in response to exposure (100×).
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Representative photomicrographs of each inflammatory cell
type taken from Diff-Quik®-stained cytospins of BALF col-
lected from WT and T-bet−/− mice at 21 days showed the
cytoplasm of macrophages and neutrophils contained nu-
merous NiNPs, whereas no NiNPs were found in lympho-
cytes or eosinophils (Figure 3E). A similar level of NiNPs
was observed in the lungs of WT mice compared to
T-bet−/− mice, although we did not quantify absolute
levels of NiNPs in lung tissue or BALF cells.
Inflammation is elevated in the lungs of WT and
T-bet−/− mice exposed to NiNPs
Inflammation of the lungs of WT and T-bet−/− mice was
evaluated by semi-quantitative scoring of H&E-stained
lung sections. Inflammatory scores revealed a significant
increase in both genotypes following NiNP exposure at
1 and 21 days post exposure when compared to their re-
spective controls (Figure 4A). At 1 day, histopathology
showed infiltration of inflammatory cells and thickeningof alveolar walls and alveolar duct bifurcations (ADB) in
response to NiNPs in WT and T-bet−/− mice (Figure 4B).
Additionally, these structural changes were also seen at
the 21 day time point in NiNP treated mice (data not
shown). Upon further evaluation, higher magnification
revealed deposition of NiNPs at ADB as well as NiNPs
contained within alveolar macrophages (Figure 4C).
Airway fibrosis is increased similarly in WT and T-bet−/− mice
exposed to NiNPs, yet NiNP-induced alveolitis is
exaggerated in T-bet−/− mice
Airway fibrosis, another characteristic associated with
the pathogenesis of allergic asthma, was measured at
21 days after NiNP exposure by performing a semi-
quantitated morphometric analysis using Adobe Photo-
shop (Figure 5A). NiNP exposure significantly increased
the thickness of airway walls as determined by quantita-
tive morphometry in both WT and T-bet−/− mice when
compared to their respective controls (Figure 5A and B).








































































Figure 4 Histopathological analysis of inflammation in the lungs of WT and T-bet−/− mice in response to NiNPs. A) Lung pathology was
scored in mice for inflammation 1 and 21 days after initial exposure. All data represent mean values ± SEM. *p < 0.05, ***p < 0.001 compared to
the control group of the same genotype (n = 5–7 animals/group). B) Representative photomicrographs at low magnification (10×) of H&E stained
lung sections at 21 days after mice were exposed. TB: Terminal bronchiole, ADB: alveolar duct bifurcation, AD: alveolar duct. C) Higher
magnification (40× and 100×) of images from 10× in (B).































































Figure 5 The effects of NiNP on airway fibrosis and parenchymal alveolitis in WT and T-bet−/− mice. A) Cross-sections of airways stained
with trichrome were measured for the area to perimeter ratio of collagen deposition. B) Representative images of results from (A) of airways
stained with trichrome (open arrows) at low magnification (10×) at 21 days post exposure. C) Lung pathology was then scored for parenchymal
lesions in WT and T-bet−/− mice. D) Low magnification (10×) of trichrome stained lung parenchyma sections (open arrows) at 21 days after WT
and T-bet−/− mice were initially exposed. Images are a representation of the data shown in (C). Black arrows indicate NiNP aggregates. Data are
the mean values ± SEM (n = 5–7 animals/group). *p < 0.05, ***p < 0.001 compared to the control group of the same genotype or as indicated.
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components within alveolar spaces along with alveolar wall
thickening (i.e., alveolitis) and typically associated with
NiNPs. However, the number and size of interstitial le-
sions, collectively termed ‘parenchymal lesion score’, were
significantly increased in T-bet−/− mice compared to WT
after NiNP exposure at 21 days (Figure 5C). The represen-
tative images from trichrome-stained lung sections shown
in Figure 5D depict the differences in parenchymal lesions
seen between WT mice and T-bet−/− mice. Mice that re-
ceived an OPA dose of 0.1% pluronic solution did not dis-
play any parenchymal lesions and were scored as a “1”.
NiNP or MWCNT exposure did not cause a significant in-
crease in whole lung col1a2 mRNA expression measured
by Taqman® quantitative RT-PCR. Moreover, NiNPs caused
no increase in lung soluble collagen protein measured by
Sircol® Assay in T-bet−/− or WT mice (Additional file 3).
NiNP-induced CCL2 mRNA and protein expression is
enhanced in T-bet−/− mice
We measured CCL2 expression since it has been impli-
cated in mucin expression as well as lung inflammation
and fibrogenesis. CCL2 mRNA expression in whole lungtissue measured by qRT-PCR was slightly increased by
NiNP exposure after 1 day in WT mice. However, a sig-
nificant increase in NiNP-induced CCL2 mRNA levels
was observed in T-bet−/− mice compared to WT mice
(Figure 6A). By 21 days, overall CCL2 mRNA levels had de-
creased but were still significant in both genotypes as com-
pared to their time-matched controls (Figure 6A). CCL2
protein levels measured in BALF mirrored that of CCL2
mRNA expression at 1 day post-exposure as T-bet−/− mice
had significantly more CCL2 protein than WT mice ex-
posed to NiNPs (Figure 6B). By 21 days, the amount of
CCL2 protein dramatically increased (~10-fold) in both
WT and T-bet−/− mice in response to NiNPs compared to
the amount of protein that was expressed in the BALF at
1 day (Figure 6B). Furthermore, CCL2 protein levels at
21 days were significantly enhanced in T-bet−/− mice com-
pared to WT mice, suggesting that the presence of T-bet
not only inhibits mucous cell metaplasia but CCL2 mRNA
and protein as well. MWCNTs also significantly increased
protein levels of CCL2 in the BALF from T-bet−/− mice,
but to a significantly lesser extent when compared to NiNP
exposure (Additional file 4). Additionally, levels of IL-13,














































































































Figure 6 CCL2 mRNA and protein levels in the lungs of mice after NiNP exposure. A) CCL2 mRNA expression was measured by qRT-PCR in
whole lung tissue at 1 and 21 days post exposure while B) CCL2 protein in BALF was analyzed by ELISA after 1 or 21 days of initial exposure (nd,
not detectable). *p < 0.05, **p < 0.01, ***p < 0.001 as compared to the control group of the same genotype or as indicated. Data are the mean
values ± SEM (n = 5–7 animals/group).
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in whole lung tissue and BALF for mRNA and protein
expression, respectively. IL-13 mRNA was increased in
response to NiNPs at 1 day post exposure in both WT
and T-bet−/− mice, yet only IL-13 protein was in-
creased in T-bet−/− mice after NiNP exposure at 1 day
(Additional file 5). MWCNTs did not cause an increase
in IL-13 levels in BALF at 1 or 21 days post-exposure
(data not shown).
Anti-CCL2 enhances NiNP-induced mucous cell metaplasia
in T-bet−/− mice
The role of CCL2 in mediating NiNP-induced mucous
cell metaplasia and alveolitis was analyzed by blocking
CCL2 activity using a monoclonal antibody. This experi-
ment was performed with T-bet−/− mice that were
treated with sequential i.p. injections of either an IgG2B
isotype control mAb or anti-CCL2 monoclonal neutral-
izing (mAb) prior to and after exposure to a single dose
of NiNPs by oropharyngeal aspiration. Necropsy was
performed only at 21 days after NiNP exposure. Lung
sections were stained with AB/PAS to Quantify* mucouscell metaplasia using the ImageJ method as previously
described above. Surprisingly, T-bet−/− mice treated with
an anti-CCL2 mAb had exaggerated NiNP-induced mu-
cous cell metaplasia (Figure 7A). Anti-CCL2 mAb also
increased NiNP-induced MUC5AC and MUC5B mRNA
levels in T-bet−/− mice (Figure 7B and C). Additionally,
at 21 days alveolitis was analyzed since there was a signifi-
cant difference between genotypes exposed to NiNPs
(Figure 5C and D). Although not significant, T-bet−/−
mice exposed to NiNPs and treated with anti-CCL2
mAb reduced the parenchymal lesion score compared to
T-bet−/− mice treated with IgG2B Isotype Control mAb
(Figure 7D). Conversely, soluble collagen measured by
the Sircol Assay was not different between isotype and
anti-CCL2 mAb treatments (Figure 7E). A small group of
WT mice were exposed to either a 0.1% pluronic solution
(n = 2) or NiNPs (n = 3) without any mAb treatments in
order to act as a repeat of the initial in vivo experiment.
All data analyzed with this group reproduced the previous
results showing that NiNP-induced mucous cell metapla-
sia and alveolitis were significantly less in WT mice com-




























































































































































































Figure 7 Mucous cell metaplasia and alveolitis in response to anti-CCL2 mAb treatment in T-bet−/− mice 21 days post-exposure.
A) Cells stained with AB/PAS were quantitated for mucin protein expression using ImageJ (NIH) analysis for percentage of positive stained area
per total area in mice treated with IgG2B Isotype Control or anti-CCL2 mAb and exposed to either a 0.1% pluronic solution or NiNPs. B) MUC5AC
and C) MUC5B whole lung mRNA expression were quantitated using qRT-PCR analysis. D) Cross sections of lungs stained with trichrome were
scored for parenchymal lesions in WT and T-bet−/− mice 21 days after initial NiNP exposure. Lungs were scored in a blinded manner by three
independent reviewers. E) Soluble collagen content was measured using the Sircol Assay kit in whole lung homogenates and expressed as μg/mg
of protein. F) Whole lung col1a2 mRNA expression measured by qRT-PCR. *p < 0.05, **p < 0.01, ***p < 0.001 compared to the time matched
control group of the same genotype or as indicated. Data are the mean values ± SEM (n = 3–5 animals/group).
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Engineered nanoparticles, including metal catalysts such
as Ni, are increasingly used for industrial purposes. Simi-
lar to micron-sized nickel particles, the major route of
exposure to nickel nanoparticles (NiNPs) is through inhal-
ation exposure [13,22,23]. Individuals with pre-existing aller-
gic lung disease or individuals with deficiencies in specific
genes, which serve to suppress allergic sensitization, would
presumably be at greater risk. In this study, we investigated
the effect of NiNPs or MWCNTs in mice lacking T-bet, a
transcription factor that serves to suppress allergic in-
flammation by maintaining a Th1 immune response
and preventing the development of a Th2 immune re-
sponse that is typical of diseases such as asthma
[8-10]. T cells in T-bet−/− mice are polarized towards a
Th2 phenotype, which mediate allergic airway remod-
eling. We found that T-bet−/− mice exposed to NiNPshad exaggerated airway mucous cell metaplasia, higher
levels of mucin gene mRNAs, and increased levels of
IL-13 and CCL2, two cytokines implicated in allergic
asthma. Moreover, NiNPs caused more severe alveolitis
in T-bet−/− mice as compared to wild-type mice. We
also observed that MWCNTs, which contain as much
as 5% Ni as residual catalyst from the manufacturing
process [20], caused significant mucous cell metaplasia
and increased CCL2, albeit to a lesser extent than
NiNPs. These findings indicate that T-bet is an import-
ant regulator of lung injury and remodeling after ex-
posure to either NiNP or MWCNTs, and that the
effect of the MWCNTs used in this study may be due
to residual Ni catalyst.
T-bet-deficient (T-bet−/−) mice have been reported to
spontaneously exhibit characteristics resembling the
pathophysiology seen in human asthma without the
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However, we did not observe obvious spontaneous
pathologic changes in airway remodeling (i.e., *mucous cell
metaplasia or airway fibrosis) in T-bet−/− mice that were
not exposed to NiNPs, but did find spontaneously in-
creased numbers of eosinophils in the BALF from T-bet−/−
mice, which is characteristic of allergic asthma. Exposure
to NiNPs caused exaggerated asthma-like airway pathology
in the T-bet−/−, but not WT, suggesting that T-bet−/− mice
are ‘primed’ for a Th2-mediated allergic response to NiNPs.
The absence of T-bet allows naïve Th cells to differentiate
into Th2 cells due to the lack of IFN-γ expression that is
produced by CD4+ cells when T-bet is present [8]. While
Th2 cells are not the only subset of Th cells that mediate
allergic lung inflammation, they still contribute to roughly
50% of the mechanisms regulating chronic airway remodel-
ing in the asthmatic population [5,25]. In addition, innate
lymphoid cells (ILCs) are a newly described type of cell
that share many functional attributes with effector T cell
subsets [10]. ILCs are important at mucosal sites where
they regulate epithelial cell homeostasis. Therefore, future
studies should focus on ILCs in the exacerbation of asthma
by nanoparticles. Interestingly, multiple studies have shown
that T-bet polymorphisms are associated with clinical
asthma phenotypes, the severity of AHR, and altered
responses to inhaled corticosteroids [24,26,27]. Given
this information, it would be beneficial to utilize T-bet−/−
mice to better understand the mechanisms behind the ex-
acerbation of asthma. While a few researchers have taken
advantage of this mouse model to study the effects bacteria
and viruses have on disease progression [28,29], to our
knowledge our study is the first to investigate the effects of
engineered nanoparticles on T-bet−/− mice. It would also
be important to determine whether nanoparticles further
alter the Th2 cell immune cell profile in T-bet−/− mice
to a Th17 response, which has been implicated in se-
vere asthma [30].
Mouse models of asthma susceptibility have been de-
veloped using 1) gene deletion (e.g., T-bet−/− mice), 2)
sensitization by repeated exposure to an allergen, or 3) a
combination of genetic deficiency and allergen challenge.
As an example of the second category, we previously re-
ported that MWCNTs manufactured with a Ni catalyst
exacerbated airway fibrosis in an ovalbumin mouse model
of allergic lung inflammation [20]. Inoue and colleagues
also showed that MWCNTs enhanced ovalbumin-induced
allergic airway inflammation and further demonstrated
that MWCNTs significantly increased allergen (OVA)-
specific syngeneic T-cell proliferation [31]. As an example
of the third category, susceptibility to MWCNT-induced
airway inflammation following ovalbumin challenge was
enhanced by the loss of cyclooxygenase-2 (COX-2) knock-
out mice, indicating that both environmental and genetic
factors are important in susceptibility to nanoparticle-induced lung injury [21]. While models of allergen-
induced airway inflammation are useful for addressing the
issue of susceptibility to engineered nanoparticles, the
T-bet−/− mouse does not require allergen sensitization
and offers the advantage of a stable genetic shift to-
wards a Th2 immune response. The stable Th2 pheno-
type of T-bet−/− mice is important since the major
pathologic phenotypes exacerbated by NiNPs (mucous
cell metaplasia and alveolitis) were observed at 21 days
post-exposure and there was little effect seen on in-
flammation at 1 day post-exposure. On the other hand,
allergen-induced mouse models of asthma are relevant
to understanding environmental susceptibility to nano-
particle exposure. While both gene deletion and aller-
gen sensitization mouse models have limitations, using
a combination of both types of mouse models is a lo-
gical approach for elucidating mechanisms of suscepti-
bility to nanoparticle exposure.
Mucus hypersecretion significantly contributes to air-
flow obstruction during asthma exacerbations that leads
to increased rates of morbidity and mortality. It is the
major cause behind fatal asthma by occluding roughly
98% of the airways [32,33]. For that reason, it is import-
ant to understand how mucous cell metaplasia and
mucin regulation is affected by NiNP exposure. Mucin
granules, detected in goblet cells by an AB/PAS stain,
were slightly increased in the airways of T-bet−/− mice
1 day after initial NiNP exposure (Figure 1). However,
examination of epithelial cells by 21 days showed that
NiNPs dramatically increased mucous cell metaplasia in
T-bet−/− mice but not WT mice. Additionally, we found
that levels of mucin mRNAs, MUC5AC and MUC5B,
correlated with the amount of mucin protein in T-bet−/−
mice that were exposed to NiNPs 21 days post-exposure
(Figure 2). This suggested that the presence of T-bet in-
hibits NiNP-induced mucous cell metaplasia, thereby re-
ducing mucin production that could lead to airway
obstruction. Interestingly, ovalbumin (OVA)-sensitized
transgenic mice overexpressing T-bet had significantly
reduced goblet cell hyperplasia and mucus hypersecre-
tion [34]. Furthermore, another study focused on OVA
sensitization in a T cell targeted, tetracycline-inducible
T-bet transgenic mouse bred on a T-bet−/− background.
That study showed that multiple features of allergic air-
way inflammation were diminished once T-bet was in-
duced by doxycycline [24]. A third study revealed that
OVA sensitized mice treated with an intranasal delivery
of T-bet attenuated goblet cell hyperplasia and eosino-
philic inflammation [35]. Therefore, our results supports
previous studies where T-bet was found to be protective
in reducing airway mucus production.
Exaggerated airway inflammation can also contribute to
airflow obstruction during asthma exacerbations [3].
Others have shown that micron-sized nickel, NiNPs, and
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ary inflammation following exposure [19,22,36]. Our data
show that acute NiNP-induced acute inflammation at
1 day was localized at alveolar duct bifurcations (ADB)
where NiNPs accumulated (Figure 4). However, there was
not a quantitative difference in lung inflammation at ADB
between NiNP-exposed WT and T-bet−/− mice as deter-
mined by pathology scoring of H&E-stained lung sections.
Interestingly, we did observe qualitative differences in
inflammatory cell profiles from the BALFs between
WT and T-bet−/− mice (Figure 3). For example, we
found that T-bet−/− mice had spontaneous eosinophil
infiltration as well as an increased number of lympho-
cytes, similar to a previous report [9]. After NiNP ex-
posure, eosinophilic inflammation was further increased
at both 1 and 21 days in T-bet−/− mice, while lymphocyte
numbers were increased at 21 days after NiNP exposure.
In contrast, WT mice displayed an inflammatory response
to NiNPs that was comprised primarily of neutrophils and
macrophages. Although it was already known that T-bet
deficiency causes lymphocytic and eosinophilic inflamma-
tion, we have shown that NiNP exposure exaggerates
these responses. Moreover, we also observed that neutro-
phils were prominent in both genotypes in response to
NiNPs. While eosinophils are typical in individuals with
mild asthma, a mixed neutrophilic and eosinophilic re-
sponse is indicative of a more severe asthma phenotype
that is more often associated with fatal asthma [3].
In addition to the development of chronic inflammation
in the lung, inhalation exposure to metallic nickel and
nickel-based particles have also been shown to induce pul-
monary fibrosis or chronic alveolitis [13,26,37-39]. We
have previously reported that MWCNTs manufactured
with a NiNP catalyst exacerbated airway fibrosis in an
OVA-induced mouse model of allergic lung inflammation
[20]. In the present study, we hypothesized that NiNPs
or MWCNTs would exacerbate airway fibrosis in the
T-bet−/− mouse model of asthma. Unlike the OVA-
induced mouse model, MWCNTs did not significantly
increase airway fibrosis or lung collagen content in T-bet−/−
mice compared to WT mice. In contrast, NiNPs increased
airway fibrosis, yet we did not observe a significant differ-
ence between WT and T-bet−/− mice (Figure 5). Alterna-
tively, a significant difference in lung parenchymal lesions
(i.e., alveolitis) was observed between the two genotypes in
response to NiNPs. In the parenchyma of the lungs of
T-bet−/− mice, NiNP exposure caused larger and more
abundant parenchymal lesions, indicating that the
presence of T-bet inhibits the progression of these par-
enchymal foci. Previous work has shown that T-bet−/−
mice are susceptible to bleomycin-induced pulmonary
fibrosis compared to WT mice [40]. We did not ob-
serve significant increases in lung collagen protein
levels using the Sircol Assay. Moreover, theparenchymal lesions were primarily a mix of inflamma-
tory cells and acellular components within alveolar
spaces, coupled with alveolar wall thickening, but con-
tained very little trichrome-positive matrix that is indi-
cative of collagen deposition and fibrosis [41].
Therefore, these parenchymal lesions were defined as
chronic alveolitis that could represent a precursor to
fibrosis. The development of alveolitis after exposure
to NiNPs could be significant in reducing lung func-
tion. Also, NiNPs were found within the parenchymal
lesions. While we did not quantify absolute levels of
NiNPs, an important focus of future studies would be
to quantify uptake and clearance of NiNPs in the lungs
of mice over time and to better understand whether
these nanoparticles traffic to other organ systems.
Monocyte chemoattractant protein-1 (MCP-1/CCL2)
is an inflammatory chemokine that has been found to
regulate the deposition of collagen, recruitment of im-
mune cells to sites of inflammation, and induction of
mucin gene expression in epithelial cells [42,43]. Previ-
ous work demonstrated that nickel oxide nanoparticles
increased CCL2 protein in the BALF of mice [44]. In
agreement with these studies, we observed that NiNPs
increased CCL2 levels in the lungs of WT mice and we
further showed that CCL2 levels were significantly en-
hanced in the lungs of T-bet−/− mice (Figure 6). During
pulmonary fibrosis, CCL2 stimulates fibroblasts to de-
posit collagen through a TGF-β1-dependent mechanism
while during inflammation acts as a chemoattractant for
a variety of immune cells including macrophages, mast
cells, eosinophils, and T helper 2 cells [45]. Elevated
levels of CCL2 have been found in the BALF and bron-
chial tissue of individuals with allergic asthma [46,47].
Therefore we hypothesized that CCL2 could be responsible
for increased mucous cell metaplasia and parenchymal al-
veolitis seen in T-bet−/− mice exposed to NiNPs. In order
to test this hypothesis, T-bet−/− mice were treated with ei-
ther anti-CCL2 mAb or an IgG2B Isotype Control mAb
before and after NiNP exposure. Neutralization of CCL2 in
allergen-induced models of asthma has been shown to de-
crease AHR, inflammation, and macrophage infiltration
[48,49]. NiNP-induced lung inflammation was not affected
in mice treated with anti-CCL2 mAb (data not shown). Al-
though CCL2 is neutralized, other ligands that bind the
CCL2 receptor, CCR2, such as MCP-5 (CCL12) and MCP-
3 (CCL7) could function to attract macrophages and eosin-
ophils and thereby regulate inflammation [50,51]. CCR2−/−
mice that have decreased amounts of CCL2 from anti-
CCL2 gene therapy treatment are protected against
bleomycin-induced pulmonary fibrosis [52,53]. While we
did not observe significant interstitial fibrosis in T-bet−/−
mice treated with NiNPs, we did observe chronic alveolitis
and found that anti-CCL2 treatment only caused a slight
decrease in alveolitis. The most significant finding was that
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mice resulted in enhanced NiNP-induced mucous cell
metaplasia (Figure 7). In addition, the anti-CCL2 neutraliz-
ing mAb enhanced NiNP-induced MUC5AC and MUC5B
mRNA expression in T-bet−/− mice. These findings are in
agreement with previous studies which demonstrated that
CCR2−/− mice have exacerbated Th2-mediated allergic air-
way responses to either OVA or Asperigillus fungal infec-
tion and demonstrate enhanced goblet cell hyperplasia
[54,55]. Therefore, CCL2 signaling appears to be an im-
portant protective mechanism in suppressing mucous cell
metaplasia caused by a variety of inhaled agents including
nanoparticles. In general, CCL2 has opposing effects in
regulating mucous cell metaplasia and alveolitis or fibrosis
in response to a variety of environmental agents including
NiNPs. The reasons for these disparate roles of CCL2 in
lung disease remain to be elucidated and require further
study.
Conclusion
In summary, our results support the hypothesis that
T-bet is an important factor in protecting the lung
from exacerbation of allergic airway inflammation and
alveolitis caused by lung injury from nickel nanoparti-
cles (NiNPs). These findings suggest that individuals
with T-bet deficiency, including individuals with asthma,
are at greater risk for the development of NiNP-induced
airway mucous cell metaplasia and alveolitis. We also
found that CCL2 is enhanced in T-bet−/− mice and block-
ing CCL2 activity with a neutralizing antibody increased
NiNP-induced mucous cell metaplasia in these mice,
while marginally reducing NiNP-induced alveolitis. There-
fore, CCL2 is a potentially important T-bet-regulated che-
mokine that appears to play a protective role in selectively
suppressing nanoparticle-induced *mucus production in
the lungs during allergic inflammation.
Methods
Animals
Pathogen-free adult male wild-type (WT) or T-bet−/−
C57BL/6 mice were obtained from Taconic Farms, Inc.
(Germantown, NY) at 6 to 11 weeks of age or The
Jackson Laboratory (Bar Harbor, ME) at 8 weeks. Mice
were housed in a temperature and humidity controlled
facility and given food and water ad libitum. All proce-
dures involving animal use were approved by the Insti-
tutional Animal Care and Use Committee (IACUC) at
North Carolina State University.
Nickel Nanoparticles (NiNPs)
Nickel nanoparticles (NiNPs) were purchased from Sun
Innovations (Fremont, CA) and have been previously
characterized [15,56]. They are characterized as spherical
in shape with a ~20 nm diameter, having a specificsurface area of 40–60 m2/g, a metal purity of 99.9%, and
insoluble in water. Size and shape have previously been
verified by measuring digitized TEM images with Adobe
Photoshop and determining pixel length of >100 NiNPs
[15]. Furthermore, the oxidation state of these NiNPs is
oxidation state (0) zero [56]. Prior to exposure, NiNPs
were suspended in a sterile, 0.1% pluronic F-68 (Sigma)
in phosphate buffered saline solution and dispersed for
two hours using a bath sonicator at room temperature.
Multiwalled Carbon Nanotubes (MWCNTs)
MWCNTs (Helix Material Solutions, Inc., Richardson, TX)
were synthesized by carbon vapor deposition (CVD) with
nickel and lanthanum catalysts. Characterization of the
size, purity, surface area and elemental composition pro-
vided by the manufacturer was verified independently
(Millennium Research Laboratories Inc., Woburn, MA)
and has been previously reported by our laboratory [20].
Experimental design
WT and T-bet−/− mice (n = 49, Taconic Farms, Inc.) were
exposed to NiNPs or MWCNTs at 4 mg/kg or 0.1%
Pluronic (Sigma Aldrich, St. Louis, MO) surfactant solution
in phosphate-buffered saline by oropharyngeal aspiration
under an isoflurane anesthetic, as previously described [57].
On day 1 or day 21 after initial NiNP exposure, mice were
euthanized via intraperitoneal injection of Fatal Plus (Vor-
tech Pharmaceuticals, Dearborn, MI). Lungs were lavaged
with Dulbecco’s phosphate-buffered saline (DPBS) and
bronchoalveolar lavage fluids (BALF) were collected for
ELISA and cell differentials. The middle and caudal lobes
of the right lung, as well as the heart, spleen, and a section
of the liver, were stored in RNAlater®, according to the
manufacturer’s instructions (Ambion, Austin, TX), and
used for TaqMan® quantitative real-time RT-PCR analysis.
The cranial lobe of the right lung was flash frozen in li-
quid nitrogen and stored at −80°C for collagen determin-
ation and protein evaluation. The left lung was infused
with 10% neutral buffered formalin, fixed for 24 hours,
transferred to 70% ethanol, and embedded in paraffin.
Three cross-sectional sections of tissue were cut and proc-
essed for histopathology with a Masson’s trichrome,
hematoxylin & eosin (H&E), or Alcian blue/periodic acid-
Schiff (AB/PAS) stain.
Monoclonal antibody administration
A second group of WT and T-bet−/− mice (n = 20, The
Jackson Laboratory) were treated with either a rat IgG2B
Isotype Control antibody (MAB0061, n = 7, R&D Sys-
tems, Minneapolis, MN) or mouse anti-CCL2 mAb
(MAB479, n = 8, R&D Systems) by intraperitoneal (i.p.)
injection before and after being exposed to 0.1% pluro-
nic solution of NiNPs as described above. Mice received
either IgG2B (25 μg) or anti-CCL2 (25 μg) mAb by i.p.
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were exposed to either the pluronic solution or NiNPs
on day 14 and euthanized via intraperitoneal injection of
Fatal Plus 21 days after NiNP exposure on day 35. Sam-
ples were collected as described in the Experimental De-
sign. Mice used in the antibody study were from The
Jackson Laboratory (Bar Harbor, ME).
Bronchoalveolar lavage and cytology
Lungs were serially lavaged three times with 0.5 mL of
DPBS and combined. An aliquot from each sample was
immediately used to analyze differential cell counts
while the remaining sample was stored at −80°C. A
Thermo Scientific Cytospin® 4 Cytocentrifuge (Thermo
Fisher Scientific, Waltham, MA) was used to plate cells
from the BALF of each animal onto glass slides. Sam-
ples were then fixed and stained with the Diff-Quik®
Stain Set (Dade Behring Inc, Newark, DE). Differential
cell counts were performed on at least 500 cells per
sample and represented as the mean ± SEM per expos-
ure group.
Lung fixation and histopathology
At necropsy, the left lungs were pressure-infused intra-
tracheally at 30 cm H2O with 10% neutral-buffered
formalin. Lungs were fixed for approximately 48 hours
and then transferred to 70% ethanol. Three cross-
sectional portions of the left lung were embedded in paraf-
fin, sectioned at 5 μm, and stained with hematoxylin
and eosin (H&E), Masson’s trichrome, or alcian-blue
periodic acid Schiff (AB-PAS) stain by established
methods.
Pathology scoring of lungs
Acute inflammation and chronic alveolitis
Three sections of lung, one each from the cranial, mid-
dle, and caudal portions of the left lung lobe from each
mouse were selected and photographed according to un-
biased criteria [58] and evaluated in a blinded fashion as
previously described [59]. Those from the 1 day time
point were scored for inflammation and those from the
21 day time point for fibrosis or alveolitis. The inflam-
mation scores reflect the averages of the scores for the
number of polymorphonuclear cells, the number and
size of intra-alveolar macrophage aggregates (these mac-
rophages were typically laden with nanoparticles), and
alveolar wall thickening. This average score was then ad-
justed for the number of nanoparticles present by divid-
ing the average score by the relative score of the number
of nanoparticles present to give an adjusted average
score. Only the lungs from the 21 day time point were
scored for fibrosis or alveolitis. The lungs were scored
for the amount of collagen present (based on Masson’s
trichrome-stained sections), the thickness of the alveolarwalls, and the number of fibroblast-like cells associated
with the particle-associated lesions. These scores were
averaged and the average scores were then divided by
the relative scores for the amount of nanoparticles
present in the lungs to give an adjusted average score for
each animal. All scores were relative scores on a scale
from 1–5, with 1 representing the levels of these param-
eters in the PBS control group, 2 representing minimal
change, 3 representing mild change, 4 representing mod-
erate change, and 5 representing severe change. In these
numeric categories, the term ‘change’ refers to the pres-
ence of intra-alveolar inflammatory cells and extracellu-
lar matrix, and alveolar wall thickening. The scores from
all three observers were averaged and the data was pre-
sented as the mean value ± SEM of the inflammation
score of 5–7 animals for each dose group. The scoring
system for acute inflammation at 1 day and parenchymal
fibrosis/alveolitis at 21 days used in this study is an un-
biased method that we have employed previously [59]
and is derived from a simple unbiased method of esti-
mating pulmonary fibrosis on a numerical scale [60].
Mucous cell metaplasia
Airway mucin production was analyzed using a previ-
ously established protocol [61]. Photomicrographs of
AB/PAS stained lung sections were measured and quan-
tified using ImageJ version 1.44o (National Institutes of
Health). All bronchioles measured for mucous cell meta-
plasia displayed cross-sectional oval or elliptical profiles
with a diameter between 100–200 micrometers [20].
Cells that were positively stained for AB/PAS were iden-
tified by the de-convolution module using a threshold
method and then calibrated for measurement in microns.
Data was expressed as the percentage of epithelial area
positively stained for AB/PAS divided by the total epithe-
lial area (%PAS+/Total Area).
Airway collagen deposition
Thickness of collagen surrounding airway bronchioles
was quantified using Adobe Photoshop CS5 (Adobe Sys-
tems, Inc., San Jose, CA) according to a previously pub-
lished procedure [62]. Photomicrographs of trichrome-
stained sections were captured using the 10× objective
on an Olympus BX41 microscope (Olympus America,
Inc., Canter Valley, PA) and digitized. All bronchioles
measured for airway fibrosis displayed cross-sectional
oval or elliptical profiles with a diameter between 100–
200 micrometers [20]. Airway collagen area was mea-
sured and corrected for length of basement membrane
(area/perimeter ratio) using the lasso tool in Adobe
Photoshop. At least three airways per animal were ana-
lyzed in a blinded, random manner and expressed as the
mean ± SEM of 5–7 animals per treatment group per
time point.
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Quantikine ELISA kits (R&D Systems) were used to
assay protein levels of IL-13 or CCL2 in BALF. Samples
were assayed according to kit instructions and absorb-
ance values were measured by the Multiskan FC micro-
plate spectrophotometer microplate reader (Thermo
Fisher Scientific).
Taqman quantitative real-time RT-PCR
One-step, TaqMan® quantitative real time RT-PCR (qRT-
PCR) was performed to quantify gene expression of our
target genes in lung tissue 1 and 21 days after NiNP ex-
posure. Total RNA was extracted and purified from the
right middle and caudal lobes of each lung using an
RNeasy™ Fibrous Tissue Mini Kit (Qiagen, Valencia,
CA). RNA concentrations were determined by the
Nanodrop® 1000 spectrophotometer and samples were
normalized to a final concentration of 25 ng/μl. qRT-PCR
was performed using reagents from the SuperScript® III
Platinum® One-Step qRT-PCR Kit (Invitrogen, Grand
Island, NY) on the StepOne® Plus instrument (Applied
Biosystems, Foster City, CA). A comparative CT method
was used to quantify target gene expression for Mucin
5 AC (MUC5AC, Mm01276718_m1), Mucin 5B (MUC5B,
Mm00466391_m1), CCL2/MCP-1 (Mm00441242_m1), IL-
13 (Mm00434204_m1), and col1a2 (Mm00483888_m1),
normalized against the endogenous control β-2 Microglob-
ulin (B2M, Mm00437762_m1) and measured relative to
the vehicle-treated control groups. Each individual sample
was analyzed in duplicate while the StepOne® Plus software
calculated relative quantitation values that were expressed
as fold-change over controls.
Sircol assay for soluble collagen
Tissue from the right cranial lobe of each mouse lung
were weighed between 10–50 mg, suspended in 1 mL of
DPBS, and homogenized for 60 seconds with a Tissue-
miser® homogenizer (Thermo Fisher Scientific). Soluble
collagen was then measured following the Sircol® Soluble
Collagen Assay kit (Biocolor Ltd., Carrickfergus, UK)
protocol as previously described [20]. Additionally, total
protein was analyzed, prior to collagen extraction, using
a BCA Protein Assay kit (Thermo Fisher Scientific).
Data were expressed as μg of soluble collagen per mg of
total protein.
Statistics
All graphs were constructed and statistical analysis was
performed using GraphPad Prism software version 5.00
(GraphPad Software, Inc., San Diego, CA). Data are the
expressed as mean values ± SEM of 5–6 (Control) or 6–
7 (NiNP) animals per genotype. Samples were assayed in
duplicate for quantitative real-time RT-PCR, triplicate
for ELISA, or as mentioned. Groups were comparedwith one-way ANOVA with a post hoc Tukey, unpaired,
two-tailed Student’s t-test, or two-way ANOVA with a
Bonferroni test. A value of p ≤ 0.05 was considered
significant.Additional files
Additional file 1: Comparison of MWCNTs and NiNPs in the
induction of airway mucous cell metaplasia and MUC5AC mRNA
levels in the lungs of WT and T-bet−/− mice. A) Quantification of mucus
producing cells at 21 days post-exposure determined using ImageJ ana-
lysis software (NIH). Data presented as the percentage of AB/PAS-positive
stained area per total area. Asterisks directly above bars (**p < 0.01 or
***p < 0.001) indicate comparison to the control group of the same
genotype. Also, a significant difference (**p < 0.01) between MWCNT and
NiNP in T-bet−/− mice is indicated. All data represent mean values ± SEM of
at least three measurements per lung of 5–7 mice per exposure group. B)
Taqman quantitative real-time RT-PCR was used to measure changes
in whole lung mRNA levels of MUC5AC Values are means ± SEM (n = 5–7
animals/group). Asterisks directly above bars (**p < 0.01 or ***p < 0.001) indi-
cate comparison to the control group of the same genotype. Also, a signifi-
cant difference (**p < 0.01) between MWCNT and NiNP in T-bet−/− mice is
indicated. MWCNT induction of MUC5AC was not significant ‘ns’ (p > 0.05).
Additional file 2: Comparison of MWCNTs and NiNPs for causing
eosinophilia or neutrophilia in the lungs of WT and T-bet−/− mice.
MWCNT or NiNP were delivered to the lungs of mice by OPA followed
by collection of lung BALF 1 day post-exposure. Relative numbers of A)
eosinophils and B) neutrophils were quantified by differential cell
counting. Data are the mean values ± SEM out of a total of 500 cells
counted per animal for 5–7 animals per dose group at 20X magnification.
Asterisks above bars (**p < 0.01 or ***p < 0.001) indicate comparison to the
saline control group of the same genotype. Significant differences (*p < 0.05,
**p < 0.01, ***p < 0.001) between MWCNT and NiNP in WT or T-bet−/− mice
are indicated. The effect of MWCNTs on eosinophilia in T-bet−/− mice was
not significant ‘ns’ (p > 0.05) compared to saline control.
Additional file 3: Comparison of NiNPs and MWCNTs in the induction
of CCL2 protein levels in BALF from the lungs of WT and T-bet−/− mice.
CCL2 protein in BALF was analyzed by ELISA after 1 day. Asterisks above bars
(*p < 0.05 or ***p < 0.001) indicate comparison to the saline control group of
the same genotype. Significant differences (**p < 0.01, ***p < 0.001) between
MWCNT and NiNP in WT or T-bet−/− mice are indicated. Data are the mean
values ± SEM (n= 5–7 animals/group).
Additional file 4: Total lung soluble collagen expression in the
lungs of WT and T-bet−/− mice in response to NiNP exposure.
A) Col1a2 mRNA expression levels were measured by qRT-PCR in whole
lung tissue at 1 and 21 days after initial exposure (nd, not detectable).
B) Soluble collagen content, μg/mg of protein, was measured from whole
lung homogenates using the Sircol Assay kit. Data are mean values ± SEM
(n = 5–7 animals/group). *p < 0.05, **p < 0.01, ***p < 0.001 as compared to
the control group of the same genotype or as indicated.
Additional file 5: IL-13 mRNA and protein expression 1 and 21 day
post exposure in the lungs of WT and T-bet−/− mice. A) Levels of
IL-13 mRNA was measured in whole lung tissue by qRT-PCR at 1 and
21 days after exposure. B) Protein expression of IL-13 in the BALF was
analyzed by ELISA at 1 or 21 days post exposure. All data represent
mean values ± SEM. *p < 0.05, **p< 0.01, ***p< 0.001 as compared to the
control group of the same genotype or as indicated (n= 5–7 animals/group).
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